The General hypothesis is that the IADPSG screening strategy for gestational diabetes (GDM) will lead to an important increase in the work load and the prevalence of GDM in Belgium but that this might not be cost effective concerning the prevention of adverse pregnancy outcomes. The risk to develop type 2 diabetes postpartum will probably be lower than for women diagnosed with the two-step screening strategy. In this prospective multicentric cohort study, women will be universally screened for pregestational diabetes and GDM at the first prenatal visit during the first trimester by measuring the fasting plasma glucose. In the second trimester, women without diagnosis of diabetes or GDM in the first trimester, will be universally screened for GDM using the 50g glucose challenge test (GCT) and the 75g oral glucose tolerance test (OGTT) with the IADPSG criteria for GDM. Diagnosis of GDM will be based on the 75g OGTT.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Difference in GDM prevalence between the 2-step and 1-step IADPSG screening strategy
Timeframe: 2 years
The difference in macrosomia rate between GDM and non-GDM groups according to the IADPSG criteria.
Timeframe: 2.5 years
The number of participants with obesity, a history of GDM, a history of prediabetes or a family history of diabetes in women with and without GDM
Timeframe: 2 years
The glucose tolerance status 3 months postpartum in women with recent GDM.
Timeframe: 3 years